Shanghai Parkinson's Study
Atslēgvārdi
Abstrakts
Apraksts
We propose to clinically examine self-reported Parkinson s disease (PD) patients from the well established Shanghai Women s Health Study (SWHS) and thus initiate a long-term PD research in this unique Chinese women cohort. The SWHS cohort was established in late 1990s by Dr. Wei Zheng from Vanderbilt University in collaboration with investigators from the Shanghai Cancer Institute (SCI) and the National Cancer Institute (NCI) of the US. Their primary aim was to examine several unique dietary hypotheses on cancer among Chinese women. From 1996 to 2000, the SWHS successfully recruited 74,942 Chinese women, aged 40 to 70, from selected communities in a single district in Shanghai with an overall consent rate of 92%. All participants completed a comprehensive baseline survey, 88% donated urine, 76% donated blood, and an additional 12% donated buccal cells.1 Follow-up surveys have since been conducted biennially with consistent participation rates of 95% or higher. Through the 3rd follow-up, the cohort has documented 220 self-reported PD cases and we expect to identify another 80 self-reports during the ongoing 4th follow-up survey (2007-2010). We hereby propose to clinically examine self-reported PD patients to achieve the following two major aims.
Aim #1: To initiate a long-term prospective study on PD in this unique Chinese women cohort
Aim #2: To examine the following specific hypotheses among women
1.
2.
3.
1. Self-reported ETS exposure is associated with a lower PD risk
2. Higher urine level of cotinine is associated with a lower PD risk
We hereby propose a prospective study on PD in a unique women-only cohort. The infrastructure and the many desirable characteristics of this cohort offer us a rare opportunity for PD research in women, particularly on biomarkers. We expect to establish it as a long-term and excellent resource for PD research in women in the future. In the short term, we plan to examine several promising PD hypotheses that have not been adequately evaluated among women. These findings will apply directly to Chinese women and may also have implications for women in the West. PD etiological research is under-represented in women. Therefore, research in the SPS may not only corroborate findings on women in the west, but also lead to the identification of novel risk factors that could be generalizable to Western women.
Datumi
Pēdējoreiz pārbaudīts: | 01/24/2018 |
Pirmais iesniegtais: | 10/19/2009 |
Paredzētā reģistrācija iesniegta: | 10/19/2009 |
Pirmais izlikts: | 10/20/2009 |
Pēdējais atjauninājums iesniegts: | 04/03/2018 |
Pēdējā atjaunināšana ievietota: | 04/04/2018 |
Faktiskais studiju sākuma datums: | 10/13/2009 |
Paredzamais pētījuma pabeigšanas datums: | 01/24/2018 |
Stāvoklis vai slimība
Fāze
Atbilstības kritēriji
Vecums, kas piemērots studijām | 40 Years Uz 40 Years |
Dzimumi, kas ir piemēroti studijām | Female |
Pieņem veselīgus brīvprātīgos | Jā |
Kritēriji | - Inclusion and exclusion criteria: This study will be conducted within the infrastructure of the Shanghai Women s Health Study. At this stage, all self-reported PD cases through the 4th follow-up will be invited. As the 4th follow-up is ongoing, we will start with cases identified from the first three follow-ups and add new cases as they are identified. Through the 3rd follow-up, a total of 220 PD patients have self-identified and 141 are incident. Assuming 200 cases are still alive at the time of the proposed study and another 80 are self-identified during the 4th follow-up, we will have approximately 280 self-reported PD patients that are eligible for the clinical confirmation at current stage. Cases identified from future SWHS follow-ups will be eligible for future SPS work. Analyses on biomarkers and genes will be conducted in a case-control manner. Overall, two controls will be selected for each case, individually matched on year of birth (+/-1), and maybe some other factors such as survival status, baseline menopausal status, fasting status, season of specimen collection, and time of the day of specimen collection. These controls have provided exposure data and/or biospecimen at baseline. Therefore at current stage no active field data collection will be carried out for controls. As at the current stage, the expected number of Parkinson cases is small, therefore we do not plan to pre-exclude any participants from this study. |
Rezultāts
Primārie rezultāti
1. A long-term prospective study of PD in this cohort [Ongoing]